The growing interest in the rapid and sustained antidepressant effects of the dissociative
anesthetic ketamine and classic psychedelics, such as psilocybin, is remarkable. However …

Major depressive disorder (MDD), commonly known as depression, affects over 300 million
people worldwide as of 2018 and presents a wide range of clinical symptoms. The …

Alzheimer's disease (AD) stands as a formidable neurodegenerative ailment and a
prominent contributor to dementia. The scarcity of available therapies for AD accentuates the …

The design of clinical protocols and the selection of drugs with appropriate posology are
critical parameters for therapeutic outcomes. Optimal therapeutic protocols could ideally be …

Objectives The purpose of this systematic review of randomized controlled trials (RCTs) was
to evaluate the effectiveness, safety, and tolerability of psilocybin in adult patients with major …

Importance Psilocybin has been studied in the treatment of depression and anxiety
disorders. Clinical studies have mainly focused on efficacy, with systematic reviews showing …

Background: Psychedelic-assisted therapy (PAT) is permitted in Switzerland under its limited
medical use program. Data from patients in this program represent a unique opportunity to …

Background Persons with schizophrenia are excluded from psychedelic-assisted therapy
due to concerns about the risk of triggering or worsening psychosis. However, there is …

Background The enduring and severe depression often suffered by Veterans causes
immense suffering and is associated with high rates of suicide and disability. This is the first …

Introduction A new era of treatment for adults with treatment-resistant depression (TRD),
which involves psychedelic substances, is dawning. Emerging evidence indicates that …